Viveve, Inc., the wholly owned subsidiary of Viveve Medical, Inc., is a women’s health company headquartered in Englewood, Colorado.
The Viveve® System is indicated for treatment of the vaginal introitus, after vaginal childbirth, to improve sexual function in Australia, Brazil, Canada, Chile, Colombia, Costa Rica, Hong Kong, Japan, Malaysia, Mexico, Panama, Philippines, Singapore, and United Arab Emirates.
The Viveve System is indicated for treatment of vaginal laxity in Bahrain, EU, Iceland, Korea, Kuwait, Lebanon, Liechtenstein, Norway, Qatar, Switzerland, Turkey, and Ukraine.
The Viveve System is indicated for use in General Surgical procedures for electrocoagulation and hemostasis in Thailand, Taiwan, and the United States.
The Viveve System is contraindicated for use in patients with either an Implantable Pacemaker or an Automatic Implantable Cardioverter/Defibrillator (AICD), or any other implantable electrical device, as they may be adversely affected by radio-frequency (RF) fields or current.
The Viveve System is not available for sale in countries not listed above.
The Viveve® System is indicated for treatment of the vaginal introitus, after vaginal childbirth, to improve sexual function in Australia, Brazil, Canada, Chile, Colombia, Costa Rica, Hong Kong, Japan, Malaysia, Mexico, Panama, Philippines, Singapore, and United Arab Emirates.
The Viveve System is indicated for treatment of vaginal laxity in Bahrain, EU, Iceland, Korea, Kuwait, Lebanon, Liechtenstein, Norway, Qatar, Switzerland, Turkey, and Ukraine.
The Viveve System is indicated for use in General Surgical procedures for electrocoagulation and hemostasis in Thailand, Taiwan, and the United States.
The Viveve System is contraindicated for use in patients with either an Implantable Pacemaker or an Automatic Implantable Cardioverter/Defibrillator (AICD), or any other implantable electrical device, as they may be adversely affected by radio-frequency (RF) fields or current.
The Viveve System is not available for sale in countries not listed above.
Location: United States, Illinois, Chicago
Phone: +1 720-696-8100
Total raised: $6.76M
Founded date: 2016
Investors 3
| Date | Name | Website |
| - | 5AM Ventur... | 5amventure... |
| - | Avoro Capi... | avorocapit... |
| - | CRG | crglp.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 19.08.2019 | - | $6.76M | - |
Mentions in press and media 18
| Date | Title | Description |
| 05.02.2022 | Viveve Medical : Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions | SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Viveve Medical, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securit... |
| 18.01.2022 | Viveve Medical : Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions | SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Viveve Medical, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 92852W5... |
| 05.01.2022 | Viveve Medical : Initial registration statement for securities to be offered to employees pursuant to employee benefit plans | As filed with the Securities and Exchange Commission onJanuary 4, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VIVEVE MED... |
| 14.12.2021 | Viveve Medical : Current report filing | false 0000879682 |
| 14.12.2021 | Viveve Medical : Announces Completion of Full Enrollment in Pivotal U.S. PURSUIT Trial for Stress Urinary Incontinence | Viveve Announces Completion of Full Enrollment in Pivotal U.S. PURSUIT Trial for Stress Urinary Incontinence Download as PDFDecember 14, 2021 Major milestone achieved in Company's advance toward a new U.S. SUI indication ENGLEWOOD, CO / ACC... |
| 12.11.2021 | Quarterly report pursuant to Section 13 or 15(d) | 0000879682 VIVE ... |
| 28.10.2021 | Viveve Announces Issuance of New Device and Methods Patent in U.S | Viveve Announces Issuance of New Device and Methods Patent in U.S Download as PDFOctober 28, 2021 Issuance further expands and strengthens Company's intellectual property portfolio ENGLEWOOD, CO / ACCESSWIRE / October 28, 2021 / Viveve Medi... |
| 23.09.2021 | Viveve Medical : Announces Issuance of New Method Patent for Stress Urinary Incontinence in Australia | Viveve Announces Issuance of New Method Patent for Stress Urinary Incontinence in Australia Download as PDFSeptember 23, 2021 Patent strengthens and expands Viveve's intellectual property portfolio for the treatment of stress urinary incont... |
| 03.08.2021 | Viveve Medical : Announces Continued Expansion of IP Portfolio with Issuance of Canadian Patent | Viveve Announces Continued Expansion of IP Portfolio with Issuance of Canadian Patent Download as PDFAugust 03, 2021 ENGLEWOOD, CO / ACCESSWIRE / August 3, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on w... |
| 08.07.2021 | Viveve Medical : Announces New Category III CPT Code for its Stress Urinary Incontinence Procedure | Viveve Announces New Category III CPT Code for its Stress Urinary Incontinence Procedure Download as PDFJuly 07, 2021 New code approved by American Medical Association and supported by key medical societies Long-term pathway for potential r... |
Show more